November 2024 in “Journal of Investigative Dermatology” Aptamers can improve wound healing and promote hair growth.
September 2024 in “Journal of the American Academy of Dermatology” PRP treatment may help improve hair density and thickness in breast cancer patients with therapy-induced hair loss.
November 2022 in “Journal of the Endocrine Society” Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
15 citations
,
February 2017 in “Nursing Clinics of North America” Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.
1 citations
,
November 2001 in “Acc Current Journal Review” Electron Beam Tomography (EBT) is a useful additional test to stress testing for detecting heart disease.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
February 2023 in “Frontiers in Bioengineering and Biotechnology” Optical imaging and light therapy show promise for diagnosing and treating liver injury caused by surgery.
January 2026 in “Journal of Biomedical Research” Small extracellular vesicles from stem and immune cells show promise for treating various diseases but face challenges in clinical use.
December 2024 in “Drug Discoveries & Therapeutics” Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
August 2025 in “Saudi Pharmaceutical Journal” The ointment effectively treats neurodermatitis and chronic eczema without causing skin irritation.
January 2023 in “Applied sciences” Equisetum debile extracts may help with skin whitening, anti-wrinkle, and anti-hair loss treatments.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
April 2023 in “Journal of Investigative Dermatology” The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
9 citations
,
August 2020 in “International Journal of Molecular Sciences” New compounds may help treat heart disease by activating specific potassium channels.
November 2025 in “Journal of Investigative Dermatology” IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
March 2019 in “SLAS TECHNOLOGY” New technologies show promise in healing wounds, treating cancer, autoimmune diseases, and genetic disorders.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
January 2026 in “SSRN Electronic Journal” 8 citations
,
June 2024 in “Pharmaceutics” PEA-ENL improves skin delivery and reduces inflammation without side effects.
1 citations
,
October 2018 in “PubMed” EK significantly improved wound healing and reduced infection in burn wounds.
8 citations
,
August 2022 in “Pharmaceutics” Erythrocyte-anchored nanoparticles improved Cepharanthine delivery and effectiveness for treating acute lung injury.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
June 2026 in “Advanced Healthcare Materials” This study introduces a taurine-based active pharmaceutical ingredient ionic liquid (CTIL) as a novel treatment for androgenic alopecia (AGA). CTIL is synthesized through a one-step method and functions both as a delivery carrier and a therapeutic agent. It effectively penetrates the skin barrier, targeting hair follicles to deliver antioxidants and modulate the perifollicular microenvironment by scavenging reactive oxygen species (ROS). In vitro studies show that CTIL's hydrogen-bond network structure enhances its penetration and accumulation in hair follicles. In an AGA animal model, CTIL reduced ROS, alleviated oxidative damage and inflammation, inhibited hair follicle miniaturization, and promoted hair regrowth. This research highlights the potential of bioactive ionic liquids in treating AGA by integrating delivery and therapeutic functions.
222 citations
,
January 2003 in “Critical Reviews in Therapeutic Drug Carrier Systems” Ethosomes can safely and effectively deliver various drugs deep into the skin.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
September 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” AR-27 E-Chol siRNA can effectively promote hair regrowth for androgenetic alopecia.
December 2013 in “Cumhuriyet Tıp Dergisi/Cumhuriyet Üniversitesi Tıp Fakültesi dergisi” Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.